FXR和HSD17B13的双调节器:在MASH中振兴FXR疗法

Changhong Wei1, Yun Liu2, Zhiming Yan2

  • 1Department of Research & Clinical Laboratory, The Fifth Affiliated Hospital of Guangxi Medical University & The First People's Hospital of Nanning, Nanning 530022, Guangxi, PR China.

PubMed
概括

法尔内索伊德X受体 (FXR) 和氧类固醇17-β脱酶13 (HSD17B13) 的双调节为脂肪肝疾病提供了一种新方法. 化合物6有效地改善了代谢功能障碍相关的脂肪肝疾病模型中的肝功能和减少炎症.